Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402987 · ClinicalTrials.gov registry record · Phase 3
Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 269
- Enrollment target
NCT00402987: Completed Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00402987 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 269 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00402987, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 269 participants
- Enrollment target
Study Summary
We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind, placebo-controlled conditions.
Primary Outcome
Based on the Pain Intensity scores measured on a Visual Analogue Scale (PI-VAS: 0mm=no pain,100mm=worst possible pain), assessed by the subjects, the SPID2 is the area under the curve (AUC) over the 2-hour period post-first dose of the Pain Intensity Difference (PID) scores using the trapezoidal rule.
Interventions
- DRUG placebo
- DRUG Celecoxib
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2006-12-04 |
| Est. Completion | 2007-11-15 |
| Phase | Phase 3 |
What the finished NCT00402987 record still lists
NCT00402987 is an interventional study that assigns participants to a tested intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00402987 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00402987 about?
NCT00402987 is a clinical study titled "Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat". We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind, placebo-controlled conditions.
What is the current status of trial NCT00402987?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 269 participants. The study started on 2006-12-04. Estimated completion is 2007-11-15.
What interventions are being tested in trial NCT00402987?
The interventions under investigation include: placebo (DRUG), Celecoxib (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00402987?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00402987's enrollment target sits among peer trials
269 1220th of 2000 higher than 779 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI